THERANEXUS SA

Theranexus lists on Euronext Growth

Theranexus lists on Euronext Growth

Theranexus, a French biotech company that develops drugs for the treatment of central nervous system disorders, celebrated today its listing on Euronext Growth (ticker code: ALTHX). Theranexus was part of the first TechShare class of 2015, and is the third company in the programme to go public, joining a community of over 330 tech companies listed on Euronext.

QUOTES   |  PRESS RELEASE   |  WWW.THERANEXUS.COM

 

Franck MOUTHON, Chairman and CEO Theranexus
Theranexus lists on Euronext Growth "The funds we raised will let us continue to proactively develop and leverage our platform and portfolio of drug candidates.”
Franck Mouthon, Chairman and CEO Theranexus

 

THERANEXUS SA

Back to previous page

Identification

ALTHX
Name: THERANEXUS SA
Market: Euronext Growth Paris
Subsector: Biotechnology
Isin code: FR0013286259
Symbol: ALTHX

Operation

IPO Date: 30/10/2017
Issue type: Initial Public offering
IPO Price: EUR 15.50
Price range: EUR 14.00 - EUR 18.80

Company Profile

Loading... Please wait.

News

Date Title
30 Oct 2017 IPO Theranexus expand

Listing of Theranexus on Euronext Growth

Franck Mouthon and Mathieu Charvériat, founders of Theranexus, open the trading day in Paris

Theranexus is an innovative biopharmaceutical company specializing in the development of therapeutic products for the treatment of central nervous system diseases. Theranexus now has one product (THN102; a drug candidate combining a modulator of neuronal activity with a glial connexin modulator for the treatment of narcolepsy, a rare neurological disease) in Phase II clinical trial.